Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 11:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 115 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 3 standard meals/day Clear all
Recruiting No phase listed Observational

Study of CAR-T Therapy in Older Patients

NCT04300998
View directory record Official record
Conditions
Lymphoma, Refractory B-Cell Lymphoma, Lymphoma, B-Cell, DLBCL NOS, High-grade B-cell Lymphoma, Multiple Myeloma
Interventions
Activities of Daily Living/ADLs, Instrumental Activity of Daily Living, Timed Up and Go, Cognition, Geriatric Depression Scale, Social Support, Brief Test of Attention, Trail Making Test, Controlled Oral Word Association Test, Hopkins Verbal Learning Test-Revised, Blood draw
Behavioral · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
60 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 3, 2026, 11:41 PM EDT
Not yet recruiting Phase 2 Interventional

Nicotinamide for Retinal Protection in Primary Open-Angle Glaucoma (NADIR Trial)

NCT07808333
View directory record Official record
Conditions
Glaucoma, Open-angle, Primary Open Angle Glaucoma (POAG)
Interventions
Nicotinamide, Standard Glaucoma Therapy
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
40 Years to 80 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 3, 2026, 11:41 PM EDT
Completed Not applicable Interventional

Cognitive Therapy for Binge-Eating Disorder

NCT00050037
View directory record Official record
Conditions
Obesity, Eating Disorders
Interventions
CBT
Procedure
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 11, 2013 · Synced Oct 3, 2026, 11:41 PM EDT
Completed Not applicable Interventional

Dyad Plus Effectiveness/Feasibility

NCT04036331
View directory record Official record
Conditions
Weight Loss, Pediatric Obesity, Overweight Adolescents, Parent-Child Relations, Family and Household
Interventions
Brenner FIT Standard, By Design Essentials, Dyad Plus
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
13 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 3, 2026, 11:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation

NCT03319173
View directory record Official record
Conditions
Mild Cognitive Impairment, Metabolic Syndrome
Interventions
Dietary intervention
Behavioral
Lead sponsor
Bristlecone Health, Inc.
Industry
Eligibility
35 Years to 80 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Maple Grove, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Oct 3, 2026, 11:41 PM EDT
Completed Phase 1 Interventional Results available

Study of Novel Antiretrovirals in Participants With HIV-1

NCT05585307
View directory record Official record
Conditions
HIV-1-infection
Interventions
Bavtavirine, B/F/TAF, Standard of Care (Substudy 01), GS-1720, Standard of Care (Substudy 02), GS-6212, Standard of Care (Substudy 03)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
38
States / cities
Long Beach, California • Los Angeles, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Oct 3, 2026, 11:41 PM EDT
Completed Not applicable Interventional

A Study of Ketogenic Diet in Newly Diagnosed Overweight or Obese Endometrial Cancer Patients

NCT03285152
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Ketogenic Diet (KD), Standard Diet (SD)
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 3, 2026, 11:41 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Comparison of Meal Replacements Versus Protein Supplements and Utilizing the Protein Digestibility Corrected Amino Acid Score (PDCAAS) Method

NCT01399333
View directory record Official record
Conditions
Protein Deficiency
Interventions
Group 1 Meal Replacement, Group 2 Protein Supplement, Group 3
Dietary Supplement
Lead sponsor
Southeast Bariatrics, PA
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 26, 2011 · Synced Oct 3, 2026, 11:41 PM EDT
Completed Not applicable Interventional Results available

Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244

NCT00970359
View directory record Official record
Conditions
Thyroid Cancer
Interventions
AZD6244
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Oct 3, 2026, 11:41 PM EDT
Terminated Phase 3 Interventional Results available

Phase 3 Study of Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil Versus Trifluridine/Tipiracil Single Agent in Participants With Previously Treated Metastatic Colorectal Cancer

NCT05223673
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
Futuximab/modotuximab, Trifluridine/Tipiracil
Biological · Drug
Lead sponsor
Institut de Recherches Internationales Servier
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Ann Arbor, Michigan • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Oct 3, 2026, 11:41 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Project 1: Diet and Exercise Modulate the Sperm Epigenome in Men

NCT04175678
View directory record Official record
Conditions
Healthy Lifestyle, Obese, Men
Interventions
Diet, Exercise, Standard care
Other
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years to 40 Years · Male only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 3, 2026, 11:41 PM EDT
Recruiting Phase 1Phase 2 Interventional

Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

NCT06374459
View directory record Official record
Conditions
Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer
Interventions
Zumsemetinib, Capecitabine, Zoledronic acid, Denosumab
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
3
States / cities
Westwood, Kansas • Rochester, Minnesota • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 3, 2026, 11:41 PM EDT
Completed Phase 2 Interventional

Pilot Study to Assess the Safety, PK and Iron Chelating Activity of DST-0509 (Deferasirox) in Thalassemia Patients Refractory to Chelation

NCT03637556
View directory record Official record
Conditions
Thalassemia Major
Interventions
DST-0509, Jadenu, Exjade
Drug
Lead sponsor
DisperSol Technologies, LLC
Industry
Eligibility
8 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 1, 2022 · Synced Oct 3, 2026, 11:41 PM EDT
Completed Not applicable Interventional

Impact of Weight Loss on Physical Function

NCT02079051
View directory record Official record
Conditions
Obesity
Interventions
Moderate intensity weight loss, High intensity medical weight loss
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
65 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Oct 3, 2026, 11:41 PM EDT
Completed Phase 4 Interventional Results available

Sitagliptin in Non-Diabetic Patients Undergoing General Surgery

NCT02741687
View directory record Official record
Conditions
Hyperglycemia
Interventions
Sitagliptin, Placebo, Supplemental insulin (insulin lispro), Supplemental insulin (insulin aspart), Long acting basal insulin (insulin detemir), Long acting basal insulin (insulin glargine)
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 27, 2018 · Synced Oct 3, 2026, 11:41 PM EDT
Recruiting Phase 1 Interventional

Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia

NCT03571321
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, ALL, Childhood, ALL
Interventions
Ruxolitinib, Cyclophosphamide, Cytarabine, Mercaptopurine, Vincristine, Pegaspargase, Rituximab, Methotrexate (Intrathecal Administration), Methotrexate (Intravenous Administration), Dexamethasone, Doxorubicin, Thioguanine, Methotrexate Oral Product
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 39 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
Chicago, Illinois • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 3, 2026, 11:41 PM EDT
Terminated Phase 3 Interventional Results available

Reparixin add-on Therapy to Standard Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia

NCT05254990
View directory record Official record
Conditions
Infectious Pneumonia, Severe COVID-19
Interventions
Reparixin, Placebo
Drug · Other
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years and older
Enrollment
414 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
28
States / cities
Tucson, Arizona • Orange, California • Denver, Colorado + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 3, 2026, 11:41 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Optimizing PTCy Dose and Timing

NCT03983850
View directory record Official record
Conditions
Graft Versus Host Disease, Hematologic Neoplasms
Interventions
Busulfan, Fludarabine, Cyclophosphamide, Mycophenolate Mofetil, Sirolimus
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years to 120 Years
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 26, 2025 · Synced Oct 3, 2026, 11:41 PM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy

NCT02755597
View directory record Official record
Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
Venetoclax, Bortezomib, Dexamethasone, Placebo for venetoclax
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
4
States / cities
Aurora, Colorado • Durham, North Carolina • Canton, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Oct 3, 2026, 11:41 PM EDT
Completed Not applicable Interventional Results available

Impact of Meal Timing on Glycemic Profile in Latino Adolescents With Obesity

NCT05391438
View directory record Official record
Conditions
Pediatric Obesity, Meal Timing
Interventions
Meal-timing
Other
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
13 Years to 19 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Oct 3, 2026, 11:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study of a Personalized vs. Standard Approach to Weight Loss Recommendations

NCT04639076
View directory record Official record
Conditions
Overweight and Obesity
Interventions
Behavioral Weight Loss Program, Personalized Behavioral Weight Loss Program
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
20 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 7, 2021 · Synced Oct 3, 2026, 11:41 PM EDT
Recruiting Not applicable Interventional

Type 1 Diabetes Management Using a Very Low Carbohydrate Versus Standard Diet

NCT03710928
View directory record Official record
Conditions
Type1diabetes
Interventions
very low carbohydrate diet, standard carbohydrate diet
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
18 Years to 40 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Oct 3, 2026, 11:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Pharmacokinetic Exposure of 2 Formulations of Apremilast in Healthy Adults

NCT02777554
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Apremilast IR, Apremilast XL
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 55 Years
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
2
States / cities
Daytona Beach, Florida • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 22, 2021 · Synced Oct 3, 2026, 11:41 PM EDT
Withdrawn Not applicable Interventional

The Inova Type 2 Diabetes Mellitus Study

NCT02222623
View directory record Official record
Conditions
Diabetes, Type 2
Interventions
Glargine, NPH
Drug
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 5, 2016 · Synced Oct 3, 2026, 11:41 PM EDT